Abacavir/dolutegravir/lamivudine

Drug Profile

Abacavir/dolutegravir/lamivudine

Alternative Names: '572-Trii; 572 Trii; Abacavir/GSK-1349572/lamivudine; Dolutegravir-Trii; Dolutegravir/abacavir/lamivudine; DTG/ABC/3TC; DTG/ABC/3TC FDC; GSK-1349572/abacavir/lamivudine; Lamivudine/abacavir/GSK-1349572; Triumeq

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline; Shionogi ViiV Healthcare LLC
  • Developer GlaxoSmithKline; Shionogi ViiV Healthcare LLC; ViiV Healthcare
  • Class Antiretrovirals; Cyclopentanes; Cyclopropanes; Dideoxynucleosides; Oxazines; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action HIV integrase inhibitors; HIV replication inhibitors; Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV infections

Most Recent Events

  • 20 Feb 2017 Blueclinical initiates enrolment in a phase II trial for HIV infections (Combination therapy) in Portugal (EudraCT2016-000346-61)
  • 20 Dec 2016 ViiV Healthcare completes a phase I bioavailability trial in Healthy volunteers in USA (PO, Dispersible Tablet) (NCT02893488)
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top